A Phase III trial showed that AstraZeneca's heart drug Brilinta is significantly more effective than blockbuster anti-clotting drug Plavix in reducing risks in patients with acute coronary syndrome. The findings, which will be presented at the European Society of Cardiology's annual meeting in August, could boost Brilinta's chances for approval.

Full Story:

Related Summaries